Cough Triggers and Symptoms Among Patients with Refractory or Unexplained Chronic Cough in Two Phase 3 Trials of the P2X3 Receptor Antagonist Gefapixant (COUGH-1 and COUGH-2)

被引：0
|
作者：
Morice, Alyn [1 ]
Birring, Surinder [2 ]
Dicpinigaitis, Peter [3 ]
McGarvey, Lorcan
Pavord, Ian [4 ]
Smith, Jaclyn [5 ]
La Rosa, Carmen [6 ]
Li, Qing [6 ]
Nguyen, Allison Martin [6 ]
Schelfhout, Jonathan [6 ]
Tzontcheva, Anjela [6 ]
Muccino, David [6 ]
机构：
[1] Univ Hull, Kingston Upon Hull, N Humberside, England
[2] Kings Coll London, London, England
[3] Jack D Weiler Hosp, Bronx, NY USA
[4] Univ Oxford, Oxford, England
[5] Univ Manchester, Manchester, Lancs, England
[6] Merck & Co Inc, Kenilworth, NJ USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2021年 / 147卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
188
引用
收藏
页码：AB61 / AB61
页数：1
相关论文
共 50 条
  • [41] BENEFITS OBSERVED WITH PATIENT-REPORTED OUTCOMES IN A PHASE 2B CLINICAL TRIAL OF GEFAPIXANT, A P2X3 RECEPTOR ANTAGONIST, IN CHRONIC COUGH
    Birring, S. S.
    McGarvey, L. P.
    Smith, J. A.
    Morice, A. H.
    Sher, M. R.
    Schelfhout, J.
    Mehta, A.
    Muccino, D. R.
    THORAX, 2019, 74 : A18 - A19
  • [42] Comparisons Of Baseline Characteristics And Treatment Efficacy In Individuals With Refractory Or Unexplained Chronic Cough Enrolled In Phase 3 Trials Of Gefapixant
    Blaiss, Michael
    Dicpinigaitis, Peter
    Birring, Surinder
    McGarvey, Lorcan
    Morice, Alyn
    Pavord, Ian
    Satia, Imran
    Smith, Jaclyn
    La Rosa, Carmen
    Li, Qing
    Nguyen, Allison Martin
    Schelfhout, Jonathan
    Tzontcheva, Anjela
    Muccino, David
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (02) : AB20 - AB20
  • [43] Safety and efficacy of P2X3 receptor antagonist for the treatment of refractory or unexplained chronic cough: A systematic review and meta-analysis of 11 randomized controlled trials
    Ramadan, Alaa
    El-Samahy, Mohamed
    Elrosasy, Amr
    Al-Tawil, Mohammed
    Abdelaziz, Ahmed
    Soliman, Mostafa A.
    Abouzid, Mohamed
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2023, 83
  • [44] The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: a randomised placebo-controlled study
    Morice, Alyn H.
    Kitt, Michael M.
    Ford, Anthony P.
    Tershakovec, Andrew M.
    Wu, Wen-Chi
    Brindle, Kayleigh
    Thompson, Rachel
    Thackray-Nocera, Susannah
    Wright, Caroline
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54 (01)
  • [45] THE EFFECT OF P2X3 ANTAGONISM (AF-219) ON EXPERIMENTALLY EVOKED COUGH IN HEALTHY VOLUNTEERS AND CHRONIC COUGH PATIENTS
    Smith, J. A.
    Kitt, M.
    Butera, P.
    Ford, A.
    THORAX, 2016, 71 : A17 - A17
  • [46] A phase 3b trial of gefapixant, a P2X3-receptor antagonist, in women with chronic cough and stress urinary incontinence
    Birring, S. S.
    Cardozo, L.
    Dicpinigaitis, P.
    Dmochowski, R.
    Afzal, A. S.
    La Rosa, C.
    Lu, S.
    Nguyen, A. Martin
    Yao, R.
    Reyfman, P.
    THORAX, 2023, 78 (SUPPL_4) : A6 - A6
  • [47] P2X3-selective mechanism of Gefapixant, a drug candidate for the treatment of refractory chronic cough
    Cui, Wen-Wen
    Wang, Si-Yu
    Zhang, Yu-Qing
    Wang, Yao
    Fan, Ying-Zhe
    Guo, Chang-Run
    Li, Xing-Hua
    Lei, Yun-Tao
    Wang, Wen-Hui
    Yang, Xiao-Na
    Hattori, Motoyuki
    Li, Chang-Zhu
    Wang, Jin
    Yu, Ye
    COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL, 2022, 20 : 1642 - 1653
  • [48] A Phase 3b Trial of Gefapixant, A P2X3-receptor Antagonist, in Women With Chronic Cough and Stress Urinary Incontinence
    Birring, S. S.
    Cardozo, L.
    Dicpinigaitis, P.
    Dmochowski, R.
    Afzal, A.
    La Rosa, C.
    Lu, S.
    Nguyen, A. Martin
    Yao, R.
    Reyfman, P.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [49] Model-based Dose Selection for Phase 3 Trials of the Selective P2X3 Antagonist Camlipixant in efractory Chronic Cough
    Chauret, N.
    Garin, M.
    Harvey, L.
    Gahir, S.
    Yang, T.
    Garceau, D.
    Bonuccelli, C. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [50] Responder Analyses for Patient-Reported Outcomes in a Pooled Analysis of Two Phase III Randomized Placebo Controlled Trials of Gefapixant, a P2X3 Receptor Antagonist for the Treatment of Chronic Cough
    Birring, S. S.
    Morice, A. H.
    Smith, J.
    McGarvey, L.
    Pavord, I. D.
    Nguyen, A. Martin
    Schelfhout, J.
    Dicpinigaitis, P.
    Iskold, B.
    Tzontcheva, A.
    Li, Q.
    Muccino, D.
    La Rosa, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
12345